- Report
- October 2024
- 207 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- November 2024
- 145 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Drug Pipelines
- March 2025
- 60 Pages
Global
From €1188EUR$1,250USD£998GBP
- Report
- January 2025
- 176 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- August 2024
- 200 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- October 2024
- 183 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- September 2021
- 262 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- May 2023
- 85 Pages
United States
From €5656EUR$5,950USD£4,752GBP
- Report
- October 2023
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
- Report
- October 2023
- 107 Pages
North America
From €3280EUR$3,450USD£2,755GBP
- Report
- April 2023
- 145 Pages
United States
From €3280EUR$3,450USD£2,755GBP
- Report
- December 2022
- 171 Pages
Africa, Middle East
From €3280EUR$3,450USD£2,755GBP
- Report
- December 2022
- 161 Pages
From €3280EUR$3,450USD£2,755GBP
- Report
- December 2022
- 181 Pages
Asia Pacific
From €3280EUR$3,450USD£2,755GBP
- Report
- December 2022
- 186 Pages
Europe
From €3280EUR$3,450USD£2,755GBP
- Report
- August 2022
- 210 Pages
Global
From €4230EUR$4,450USD£3,554GBP
- Report
- April 2023
- 164 Pages
Global
From €9031EUR$9,500USD£7,587GBP
- Report
- August 2022
- 119 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- March 2024
- 134 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP

The Intravenous Immunoglobulin (IVIG) market is a subset of the biotechnology industry that focuses on the production and distribution of immunoglobulin products. IVIG is a blood product derived from the pooled plasma of healthy donors, and is used to treat a variety of conditions, including autoimmune diseases, infections, and immunodeficiencies. IVIG is also used in the prevention of certain infections in immunocompromised patients.
IVIG is produced by a number of companies, including CSL Behring, Grifols, Kedrion, Octapharma, and Biotest. These companies are involved in the production, distribution, and marketing of IVIG products. They also provide support services such as patient education, reimbursement assistance, and clinical trial support. Additionally, some companies are involved in the development of new IVIG products, such as recombinant immunoglobulins and monoclonal antibodies. Show Less Read more